Across five clinical studies, oral semaglutide consistently reduced systolic blood pressure by 2.6-12.7 mmHg and total cholesterol by 8.8-22.2 mg/dL in type 2 diabetes patients, suggesting cardiovascular benefits comparable to injectable semaglutide.
SBP reduced up to 12.7 mmHgConsistent systolic blood pressure reduction across all five studies of oral semaglutide in type 2 diabetes patients
What the researchers found
All five included studies showed consistent systolic blood pressure reductions with oral semaglutide, ranging from -2.60 to -12.74 mmHg. Diastolic blood pressure effects were less consistent. Total cholesterol was reduced across all studies (-8.80 to -22.19 mg/dL). Four of five studies reported favorable LDL cholesterol reductions (-7.6 to -18.0 mg/dL) and triglyceride reductions (-11.00 to -40.13 mg/dL).
HDL cholesterol showed the least consistent pattern: three studies found a non-significant increasing trend, while one reported a mild increase. The authors concluded that oral semaglutide may offer cardiovascular benefits comparable to subcutaneous semaglutide, with the advantage of improved patient adherence.
Why it matters
Cardiovascular disease is the leading cause of death in type 2 diabetes patients. Injectable semaglutide has proven cardiovascular benefits, but many patients resist or struggle with injections. If the oral form provides comparable cardiovascular protection, it could significantly expand the number of patients who benefit from this drug — particularly in populations where injection therapy faces cultural or practical barriers.
How the study worked
Systematic review following PRISMA guidelines, searching eight databases (Scopus, PubMed, Cochrane Library, and others). Included clinical studies using oral semaglutide added to standard diabetes treatment versus placebo, assessing cardiovascular risk factors prospectively or in RCT design. Five studies met inclusion criteria (2 RCTs, 3 prospective observational). Bias assessed via Newcastle-Ottawa and Jadad scales.
What this study cannot tell us
Only five studies were included, and three were observational rather than randomized. No meta-analysis was performed due to heterogeneity. The review assessed cardiovascular risk factors (blood pressure, lipids) as surrogate endpoints rather than hard cardiovascular events (heart attacks, strokes, death). Direct head-to-head comparisons of oral versus subcutaneous semaglutide on cardiovascular outcomes are lacking.
How to read the evidence
This is a systematic review of five clinical studies (2 RCTs and 3 prospective observational studies). While it follows PRISMA guidelines and uses bias assessment tools, the small number of included studies and lack of meta-analysis limit the evidence strength. Surrogate endpoints were assessed rather than hard cardiovascular outcomes.
When this study was published
Published in 2025, this is a very current systematic review reflecting the growing evidence base for oral semaglutide's cardiovascular effects as the drug becomes more widely prescribed.
The bigger picture
This review addresses a key question in the GLP-1 agonist field: does the convenience of an oral formulation come at the cost of reduced efficacy? The consistent cardiovascular risk factor improvements suggest it does not, which has implications for treatment guidelines and insurance coverage decisions. As oral GLP-1 formulations improve and higher doses become available, the gap between oral and injectable forms may narrow further.
Questions still open
- Do the cardiovascular risk factor improvements with oral semaglutide translate to reduced cardiovascular events in dedicated outcome trials?
- How does the higher-dose oral semaglutide (25 mg and 50 mg) compare to injectable semaglutide for cardiovascular risk factor modification?
- Are there patient subgroups that benefit more from oral versus injectable semaglutide for cardiovascular protection?
Common questions
Is oral semaglutide as effective as the injectable version for heart health?
Why would patients choose oral semaglutide over the injection?
Read the original research
The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review.
Journal of clinical medicine, 14(7)
Citation
Krishnanda, Stanislaus Ivanovich; Christabelle, Marie; Yausep, Oliver Emmanuel; Sugiharto, Caroline; Vincent, Leroy David; Agarwal, Raksheeth; Damara, Ivan; Harbuwono, Dante Saksono. (2025). The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review.. Journal of clinical medicine, 14(7). https://doi.org/10.3390/jcm14072239